Evidence map›Paper›PMID 27104982›Full record

ArticleCancer biology & therapy2016

TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway.

Yu Gan, Yong Wang, Zhengyu Tan, Jun Zhou, Riko Kitazawa, Xianzhen Jiang, Yuxin Tang, Jianfu Yang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Regulation of Molecular Targets in Osteosarcoma Treatment.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. METTL3 potentiates resistance to cisplatin through mJournal of cellular and molecular medicine · 2020
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yu Gana Department of Urology , The Third Xiangya Hospital of Central South University , Changsha , PR China.
Yong Wanga Department of Urology , The Third Xiangya Hospital of Central South University , Changsha , PR China.
Zhengyu Tana Department of Urology , The Third Xiangya Hospital of Central South University , Changsha , PR China.
Jun Zhoua Department of Urology , The Third Xiangya Hospital of Central South University , Changsha , PR China.
Riko Kitazawab Department of Diagnostic Pathology , Ehime University Hospital, Shitsukawa , Tōon , Ehime Perfecture , Japan.
Xianzhen Jianga Department of Urology , The Third Xiangya Hospital of Central South University , Changsha , PR China.
Yuxin Tanga Department of Urology , The Third Xiangya Hospital of Central South University , Changsha , PR China.
Jianfu Yanga Department of Urology , The Third Xiangya Hospital of Central South University , Changsha , PR China.
Central South University · CNThird Xiangya Hospital · CNEhime University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously identified TDRG1 (testis developmental related gene 1), a novel gene with exclusive expression in testis, promoted the proliferation and progression of cultured human seminoma cells through PI3K/Akt/mTOR signaling. As increasing evidence reveal that aberrant activation of this signaling is involved in cisplatin resistance. Then, in this study, we further explored whether TDRG1 regulated the chemosensitivity of seminoma TCam-2 cells to cisplatin. Our researches showed TDRG1 could regulate the viability of TCam-2 cells following cisplatin treatment in vitro through control of both cell apoptosis and cell cycle. Mechanistically, we observed TDRG1 positively regulated the expression levels of the key elements in PI3K/Akt/mTOR pathway including p-PI3K, p-Akt and p-mTOR and also affected the translocation of nuclear p-Akt in TCam-2 cells during cisplatin treatment. Meanwhile, the levels of Bad, cytochrome c, caspase-9 ratio (activated/total), caspase-3 ratio (activated/total) and cleaved-PARP were negatively modulated by TDRG1, which meant the involvement of mitochondria-mediated apoptotic pathway. Furthermore, we found the effect of TDRG1 knockdown or TDRG1 overexpression could be reversed by IGF-1, a PI3K signaling activator, or LY294002, a inhibitor of this pathway, respectively. Similar effects of TDRG1 on cisplatin chemosensitivity and associated molecular mechanism were also confirmed in vivo by employing xenograft assays. In addition, the positive correlation between TDRG1 and p-PI3K, or p-Akt, was found in tumor tissues from seminoma patients. In conclusion, we uncover that TDRG1 regulates chemosensitivity of TCam-2 cells to cisplatin through PI3K/Akt/mTOR signaling and mitochondria-mediated apoptotic pathway both in vitro and in vivo.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCisplatinHumansImmunohistochemistryMaleMiceMice, NudeMitochondriaPhosphatidylinositol 3-KinasesProteinsProto-Oncogene Proteins c-aktRNA, Long NoncodingSeminomaSignal TransductionAntineoplastic AgentsCisplatinMTOR protein, humanPhosphatidylinositol 3-KinasesProteinsProto-Oncogene Proteins c-aktRNA, Long NoncodingTDRG1 long non-coding RNA, humanTOR Serine-Threonine KinasesAktapoptosischemosensitivity; cisplatinPI3KTDRG1testicular seminoma

Identifiers

PMID27104982
PMCPMC4970539
OpenAlexW2341327015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.